569
Views
13
CrossRef citations to date
0
Altmetric
Review

The risk of cardiovascular complications with current obesity drugs

ORCID Icon, , , &
Pages 1095-1104 | Received 02 Jun 2020, Accepted 03 Aug 2020, Published online: 09 Sep 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Daiki Kojima, Naoki Washida, Kiyotaka Uchiyama, Eriko Yoshida Hama, Tomoki Nagasaka, Ei Kusahana, Takashin Nakayama, Kengo Nagashima, Yasunori Sato, Kohkichi Morimoto, Takeshi Kanda & Hiroshi Itoh. (2023) The body mass index change is associated with death or hemodialysis transfer in Japanese patients initiating peritoneal dialysis. Renal Failure 45:1.
Read now
Win Min Oo, Ali Mobasheri & David J Hunter. (2022) A narrative review of anti-obesity medications for obese patients with osteoarthritis. Expert Opinion on Pharmacotherapy 23:12, pages 1381-1395.
Read now

Articles from other publishers (11)

Siwoo Jeong, Sung Bum Yun, Soon Yong Park & Sungchul Mun. (2023) Understanding cross-data dynamics of individual and social/environmental factors through a public health lens: explainable machine learning approaches. Frontiers in Public Health 11.
Crossref
Dhanush Haspula & Zhenzhong Cui. (2023) Neurochemical Basis of Inter-Organ Crosstalk in Health and Obesity: Focus on the Hypothalamus and the Brainstem. Cells 12:13, pages 1801.
Crossref
Jie ZHANG, Hongyan HU & Li XU. (2023) Analysis of the role of risk control in preventing the occurrence of intraoperative nursing risks in elderly cardiovascular patients. Minerva Surgery 78:3.
Crossref
Tengteng Ping, Min Zheng, Pingping Zhang, Tianhao Yan, Xufeng Miao, Ke Wang & Kaoqi Lian. (2022) Determination of 12 anti-obesity drugs in human plasma by a 96-well protein precipitation plate using HPLC-MS. RSC Advances 12:40, pages 26016-26022.
Crossref
Naphatsanan Duansak, Geert W. Schmid-Schönbein & Umarat Srisawat. (2022) Anti-Obesity Effect of Rice Bran Extract on High-Fat Diet-Induced Obese Mice. Preventive Nutrition and Food Science 27:2, pages 172-179.
Crossref
David J Heal & Sharon L Smith. (2021) Prospects for new drugs to treat binge-eating disorder: Insights from psychopathology and neuropharmacology. Journal of Psychopharmacology 36:6, pages 680-703.
Crossref
Yalin Liu & Xianghang Luo. (2022) New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation. Frontiers of Medicine 16:1, pages 17-24.
Crossref
Yuan-Yuan Lang, Xin-Yue Xu, Yan-Ling Liu, Chun-Feng Ye, Na Hu, Qing Yao, Wen-Shu Cheng, Zu-Gen Cheng & Yang Liu. (2022) Ghrelin Relieves Obesity-Induced Myocardial Injury by Regulating the Epigenetic Suppression of <b><i>miR-196b</i></b> Mediated by lncRNA HOTAIR. Obesity Facts 15:4, pages 540-549.
Crossref
Reem Odi, Roberto William Invernizzi, Tamar Gallily, Meir Bialer & Emilio Perucca. (2021) Fenfluramine repurposing from weight loss to epilepsy: What we do and do not know. Pharmacology & Therapeutics 226, pages 107866.
Crossref
Young Jin Tak & Sang Yeoup Lee. (2021) Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?. Current Obesity Reports 10:1, pages 14-30.
Crossref
Tengteng Ping, Min Zheng, Pingping Zhang, Tianhao Yan, Xufeng Miao, Kaoqi Lian & Ke Wang. (2022) Simultaneous Determination of 12 Anti-Obesity Drugs in Human Plasma by a 96-Well Protein Precipitation Plate Coupled with High-Performance Liquid Chromatography–Mass Spectrometry. SSRN Electronic Journal.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.